Drug Trial Radar · NCT06091865
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
904
Planned (sponsor's estimate)
Start
Dec 13, 2023
Primary completion
Mar 30, 2028
Study completion Sep 12, 2029
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Oct 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treated before (called "previously untreated"). Patients with DLBCL that have come back after treatment (called "relapsed"), or have not responded to treatment (called "refractory"), can also participate in this study. This study will be made up of Part 1A, Part 1B, and Part 2.The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy in Part 2 of the study. The aim of Part 2 of the study is to see how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab (the comparator drug), and chemotherapy, the current standard of care treatment approved for DLBCL. Standard of care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug when combined with chemotherapy * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * The impact from the study drug on quality of life and ability to complete routine daily activities
Conditions
- Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
OdronextamabDrug
Odronextamab will be administered by intravenous (IV) infusion
RituximabDrug
Rituximab will be administered IV, or subcutaneously (SC)
CyclophosphamideDrug
Cyclophosphamide will be administered IV as part of chemotherapy
DoxorubicinDrug
Doxorubicin will be administered IV as part of chemotherapy
VincristineDrug
Vincristine will be administered IV as part of chemotherapy
Prednisone/PrednisoloneDrug
Prednisone or prednisolone will be administered orally (PO) as part of chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs)Time frame: Up to 35 days
- Incidence of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 2 years
- Severity of TEAEsTime frame: Up to 2 years
- Progression Free Survival (PFS), assessed by Independent Central Review (ICR)Time frame: Up to 5 years
Locations
195 sites in 21 countries. Site status is shown where the registry gives one.
Mayo Clinic - Arizona
Scottsdale, Arizona · Recruiting
David Geffen School of Medicine at UCLA
Los Angeles, California · Recruiting
University of California Irvine Medical Center
Orange, California · Recruiting
UC Davis Comprehensive Cancer Center
Sacramento, California · Withdrawn
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana · Recruiting
St Vincent Ascension at Peyton Manning Childrens Hospital
Indianapolis, Indiana · Recruiting
Investigative Clinical Research of Indiana
Noblesville, Indiana · Recruiting
University of Kentucky
Lexington, Kentucky · Recruiting
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Henry Ford Health System
Detroit, Michigan · Recruiting
Cancer and Hematology Centers of Western Michigan
Grand Rapids, Michigan · Recruiting
Mayo Clinic - Rochester
Rochester, Minnesota · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
Stony Brook University Hospital
Stony Brook, New York · Recruiting
Clinical Research Alliance Inc
Westbury, New York · Withdrawn
Duke University Medical Center
Durham, North Carolina · Recruiting
East Carolina University
Greenville, North Carolina · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
Center for Oncology and Blood Disorders
Houston, Texas · Withdrawn
Community Cancer Trials of Utah
Ogden, Utah · Recruiting
Prohealth Care Inc
Waukesha, Wisconsin · Withdrawn
Liverpool Hospital
Liverpool, New South Wales, Australia · Recruiting
Calvary Mater Newcastle
Waratah, New South Wales, Australia · Recruiting
Icon Cancer Centre - Wesley
Auchenflower, Queensland, Australia · Recruiting
Pindara Private Hospital
Benowa, Queensland, Australia · Recruiting
Epworth Freemasons
East Melbourne, Victoria, Australia · Recruiting
Medical University Graz
Graz, Austria · Recruiting
Medical University of Vienna
Vienna, Austria · Recruiting
Hanusch Krankenhaus
Vienna, Austria · Recruiting
Klinikum Wels-Grieskirchen
Wels, Austria · Recruiting
Landeskrankenhaus Hochsteiermark
Leoben, Styria, Austria · Recruiting
Kepler University Hospital
Linz, Upper Austria, Austria · Recruiting
Institut Jules Bordet
Brussels, Belgium · Recruiting
AZ St.-Elisabeth Herentals vzw
Herentals, Antwerp, Belgium · Recruiting
Centre Hospitalier Regional de Verviers
Verviers, Liege, Belgium · Recruiting
Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital
Ghent, Oost-Vlaanderen, Belgium · Recruiting
Algemeen Ziekenhuis AZ Delta
Roeselare, West-Vlaanderen, Belgium · Recruiting
Instituto Nacional de Cancer Jose Alencar Gomes da Silva
Rio de Janeiro, Brazil · Recruiting
Showing 40 of 195 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.